Evidence map›Paper›PMID 27190616›Full record

ArticleClinical case reports2016

Asenapine augmentation in bipolar disorders: a case series.

Donatella Marazziti, Federico Mucci, Stefano Baroni, Armando Piccinni

Abstract readCase Reports
In one paragraph

Article in Clinical case reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Donatella MarazzitiDipartimento di Medicina Clinica e Sperimentale Section of Psychiatry University of Pisa Pisa Italy.
Federico MucciDipartimento di Medicina Clinica e Sperimentale Section of Psychiatry University of Pisa Pisa Italy.
Stefano BaroniDipartimento di Medicina Clinica e Sperimentale Section of Psychiatry University of Pisa Pisa Italy.
Armando PiccinniDipartimento di Medicina Clinica e Sperimentale Section of Psychiatry University of Pisa Pisa Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Asenapine, a novel second-generation antipsychotic is effective in acute treatment of bipolar I disorder patients in combination with mood stabilizers even in resistant cases. Although there is no evidence for asenapine's efficacy to be superior to currently available agents, asenapine's favorable weight and metabolic profile are of clinical interest.

Indexed as

Antipsychoticsasenapinebipolar disorderssecond‐generation antipsychotics

Identifiers

PMID27190616
PMCPMC4856245

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.